Lan Wang, MD
Internal Medicine · Santa Clara
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 4
- 1 carrier
- Office
- 1
- Since medical school
- 10 years
- Drexel University College of Medicine, 2016
Offices
1 location · Permanente Medical Group Inc · 10,928 clinicians in this group
Looking this up.
Plans that list them
4 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Wang’s office at (408) 851-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Kaiser Permanente Dual Complete North P2 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Dual Complete North P23 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Basic Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Enhanced Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
Drugs they prescribed that Part D paid
$2,563,263
Pharmacies billed $2,563,263 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their Part D prescriptions (21 of 620) in 2024. Above the middle of the specialty; the typical internal medicine clinician is at 1%. Long-acting opioids: 52% of their opioid prescriptions.
504 generic and 116 brand-name prescriptions · $2,563,263 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lenalidomide | 122 | $1,381,539 | $11,324 |
| Brukinsa | 32 | $421,532 | $13,173 |
| Imbruvica | 13 | $231,382 | $17,799 |
| Calquence | 12 | $172,372 | $14,364 |
| Atovaquone | 11 | $3,712 | $337 |
See all 14 drugs
| Lenalidomide | 122 | $1,381,539 | $11,324 |
| Brukinsa | 32 | $421,532 | $13,173 |
| Imbruvica | 13 | $231,382 | $17,799 |
| Calquence | 12 | $172,372 | $14,364 |
| Atovaquone | 11 | $3,712 | $337 |
| Hydroxyurea | 68 | $2,871 | $42 |
| Acyclovir | 56 | $1,550 | $28 |
| Entecavir | 21 | $1,446 | $69 |
| Dexamethasone | 43 | $801 | $19 |
| Anastrozole | 21 | $588 | $28 |
| Morphine Sulfate Er | 11 | $370 | $34 |
| Prednisone | 33 | $247 | $7 |
| Mirtazapine | 13 | $217 | $17 |
| Allopurinol | 12 | $118 | $10 |
Year by year
| 2024 | 620 | 113 | 3% (21) | 19% | $2,563,263 |
| 2023 | 470 | 86 | 7% (33) | 15% | $2,243,654 |
| 2022 | 178 | 52 | 8% (15) | 22% | $1,033,537 |
| 2021 | 124 | 38 | 19% (23) | 24% | $233,973 |
| 2020 | 141 | 45 | 16% (22) | 31% | $374,982 |
| 2019 | 282 | 54 | None | None | $105,129 |
| 2018 | 408 | 74 | None | None | $29,775 |
| 2017 | 61 | 16 | 0% (0) | None | $6,552 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Lenalidomide | 115 | $1,391,839 | $12,103 |
| Pomalyst | 14 | $237,782 | $16,984 |
| Brukinsa | 18 | $221,170 | $12,287 |
| Imbruvica | 12 | $206,948 | $17,246 |
| Hydroxyurea | 63 | $2,747 | $44 |
| Dexamethasone | 27 | $866 | $32 |
| Anastrozole | 25 | $646 | $26 |
| Acyclovir | 15 | $403 | $27 |
| Entecavir | 13 | $346 | $27 |
| Prednisone | 32 | $259 | $8 |
| Oxycodone | 18 | $241 | $13 |
2022: 2 drugs
| Lenalidomide | 48 | $580,884 | $12,102 |
| Pomalyst | 11 | $224,524 | $20,411 |
2021: 1 drug
| Ondansetron | 11 | $246 | $22 |
2020: 1 drug
| Hydrocodone-Acetaminophen | 13 | $382 | $29 |
2019: 6 drugs
| Levothyroxine | 13 | $328 | $25 |
| Atorvastatin | 18 | $298 | $17 |
| Tamsulosin | 16 | $230 | $14 |
| Amlodipine Besylate | 19 | $84 | $4 |
| Losartan | 11 | $74 | $7 |
| Metoprolol | 11 | $68 | $6 |
2018: 8 drugs
| Levothyroxine | 32 | $770 | $24 |
| Atorvastatin | 26 | $508 | $20 |
| Metformin | 19 | $141 | $7 |
| Benazepril | 18 | $131 | $7 |
| Omeprazole | 19 | $126 | $7 |
| Amlodipine Besylate | 23 | $110 | $5 |
| Furosemide | 12 | $100 | $8 |
| Lisinopril | 17 | $93 | $5 |
Money from drug and device companies
$600 in 2022
| 2022 | 8 | 20 | None | $600 |
| 2021 | 6 | 14 | None | $1,190 |
| 2020 | 9 | 18 | None | $922 |
| 2019 | 11 | 14 | None | $1,219 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Jazz Pharmaceuticals | Rylaze | $125 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Pomalyst | $88 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $79 | 4 payments
|
| Amgen | Nplate | $75 | 4 payments
|
| Celgene | Pomalyst | $73 | 3 payments
|
| Incyte | Jakafi | $67 | 3 payments
|
See all 20 published payments
| Merck Sharp & Dohme | Meals · 2022-06-28 | Keytruda | $24 |
| Genzyme | Meals · 2022-06-21 | Elitek | $29 |
| E.R. Squibb & Sons L.L.C. | Meals · 2022-06-15 | Pomalyst | $88 |
| Amgen | Meals · 2022-06-13 | Lumakras | $21 |
| Celgene | Meals · 2022-06-09 | Pomalyst | $25 |
| Eisai | Meals · 2022-05-12 | Lenvima | $24 |
| Incyte | Meals · 2022-05-11 | Jakafi | $27 |
| Incyte | Meals · 2022-04-21 | Jakafi | $27 |
| Merck Sharp & Dohme | Meals · 2022-04-21 | Keytruda | $22 |
| Celgene | Meals · 2022-04-12 | Pomalyst | $23 |
| Genzyme | Meals · 2022-04-05 | Sarclisa | $25 |
| Jazz Pharmaceuticals | Meals · 2022-03-16 | Rylaze | $125 |
| Merck Sharp & Dohme | Meals · 2022-03-14 | Keytruda | $14 |
| Amgen | Meals · 2022-03-09 | Nplate | $16 |
| Amgen | Meals · 2022-03-08 | Blincyto | $23 |
| Celgene | Meals · 2022-02-24 | Pomalyst | $25 |
| Incyte | Meals · 2022-02-10 | Jakafi | $12 |
| Amgen | Meals · 2022-01-31 | Nplate | $15 |
| Merck Sharp & Dohme | Meals · 2022-01-27 | Keytruda | $18 |
| Eisai | Meals · 2022-01-13 | Lenvima | $17 |
See earlier years (2021, 2020, 2019)
2021: $1,190
| Genzyme | Sarclisa | $287 | 4 payments
|
| Jazz Pharmaceuticals | Defitelio | $251 | 2 payments
|
| Seagen | Adcetris | $247 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $243 | 2 payments
|
| Alexion Pharmaceuticals | Ultomiris | $104 | 1 payment
|
| Amgen | Nplate | $58 | 3 payments
|
2020: $922
| Celgene | Inrebic | $420 | 8 payments
|
| Amgen | Nplate | $126 | 2 payments
|
| Epizyme | Tazverik | $125 | 1 payment
|
| Alexion Pharmaceuticals | None | $125 | 1 payment
|
| Incyte | Jakafi | $42 | 2 payments
|
| Seagen | Adcetris | $25 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Calquence | $21 | 1 payment
|
| Genzyme | Sarclisa | $19 | 1 payment
|
| Jazz Pharmaceuticals | Vyxeos | $18 | 1 payment
|
2019: $1,219
| AstraZeneca Pharmaceuticals LP | Lynparza | $243 | 2 payments
|
| Exelixis | Cabometyx | $160 | 2 payments
|
| Jazz Pharmaceuticals | Vyxeos | $125 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $123 | 1 payment
|
| Akcea Therapeutics | Tegsedi | $119 | 1 payment
|
| Agios Pharmaceuticals | Tibsovo | $113 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $112 | 1 payment
|
| Alexion Pharmaceuticals | Soliris | $100 | 1 payment
|
| Amgen | Blincyto | $88 | 2 payments
|
| Incyte | Jakafi | $19 | 1 payment
|
| Pfizer | Besponsa | $17 | 1 payment
|
Professional record
- NPI
- 1720432420
- Trained
- Drexel University College of Medicine, 2016 · 10 years ago
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Medicaid ID
- CA LW3232267556
- Taxonomy
- Student in a training program (390200000X)
- Mailing address
- 1725 S Bascom Ave Apt 216, Campbell, CA, 95008
- NPI first listed
- 2016-04-19
- NPI last updated
- 2022-08-07
- NPI record certified
- 2022-08-07
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.